IBD
Pharma

Vanda's Nereus scores ph3 win in GLP-1 related nausea

Vanda's Nereus reduced GLP-1-related vomiting and nausea in a phase 3 trial.
Donavyn Coffey Oct 27, 2026 4:30pm
closed close

Teva to shut down 'underutilized' New Jersey drug facility

Oct 27, 2026 4:17pm
Novartis

Novartis CEO unfazed by high-profile clinical failures

Oct 27, 2026 11:40am
An arrow incrementally going up stairs before pointing straight up Blue background

Elrexfio ph. 3 win tees up label expansion in multiple myeloma

Oct 27, 2026 11:15am
WuXi

WuXi AppTec has performed well in '26 despite US uncertainties

Oct 27, 2026 10:07am
Law Legal System Justice Crime concept Mallet Gavel Hammer and Scales on tabl

Lilly fends off Novo’s legal bid to block GLP-1 marketing claims

Oct 27, 2026 10:06am
More News

Regeneron to collect $270M in renewed US Ebola drug supply deal

Oct 27, 2026 9:28am

Sun rises on a new Leqselvi marketing era with first DTC ad

Oct 27, 2026 8:21am

Pfizer’s Talzenna combo moves up treatment line with FDA nod

Oct 26, 2026 3:27pm

Merck sees ‘pretty consistent’ data in sac-TMT’s 1st global ph. 3

Oct 26, 2026 11:30am